Clinical Trials Browser

Thyroid Carcinoma, Anaplastic × trametinib × 1 year × Clear all

NCT03975231 2026-04-08

Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer

Phase 1 Recruiting

EndocrineHead & Neck

Thyroid Carcinoma, Anaplastic

NCT07440290 2026-02-27

DETERMINE

Phase 2/3 Not yet recruiting

CNSEndocrineGastrointestinalGynecologicHead & NeckLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Thyroid Cancer, Papillary, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Glioma, Histiocytosis, Langerhans-Cell, Laryngeal Neoplasms, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Ovarian Neoplasms, Colorectal Neoplasms, Hematologic Neoplasms, Erdheim-Chester Disease, Thyroid Carcinoma, Anaplastic

NCT04675710 2026-02-19

Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer

Phase 2 Active not recruiting

EndocrineHead & Neck

Thyroid Carcinoma, Anaplastic

NCT03085056 2025-07-03

Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer

Phase EARLY_PHASE1 Active not recruiting

EndocrineHead & Neck

Thyroid Carcinoma, Anaplastic

NCT04238624 2025-07-02

Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer

Phase 2 Active not recruiting

EndocrineHead & Neck

Thyroid Neoplasms, Thyroid Carcinoma, Anaplastic